Hot-selling High Quality CAS 78-96-6 99% Amino-2-Propanol / Isopropanolamine/ Monoisopropanolamine (MIPA)

We constantly believe that one’s character decides products’ high quality, the details decides products’ high-quality ,together with the REALISTIC,EFFICIENT AND INNOVATIVE crew spirit for Hot-selling High Quality CAS 78-96-6 99% Amino-2-Propanol / Isopropanolamine/ Monoisopropanolamine (MIPA), We are going to make increased attempts to aid domestic and international buyers, and generate the mutual benefit and win-win partnership between us. we are eagerly waiting for your sincerely cooperation.
We constantly believe that one’s character decides products’ high quality, the details decides products’ high-quality ,together with the REALISTIC,EFFICIENT AND INNOVATIVE crew spirit for China Mipa and Monoisopropanolamine, We integrate design, manufacture and export together with more than 100 skillful workers, strict quality controlling system and experienced technology.We keep long term business relationships with wholesaler and distributors form more than 50 countries, such as USA, UK, Canada, Europe and Africa etc.

3′-Amino-2′-hydroxy-[1,1'-bipheny]-3-carboxylic acid is used as the intermediate of Eltrombopag .
Eltrombopag, developed by GlaxoSmithKline (GSK) in the UK and later jointly developed with Novartis in Switzerland, is the first and only approved small molecule non peptide TPO receptor agonist in the world. Eltrombopag was approved by the US FDA in 2008 for the treatment of idiopathic thrombocytopenic purpura (ITP), and in 2014 for the treatment of severe aplastic anemia (AA). It is also the first drug approved by the US FDA for the treatment of AA in recent 30 years.
In december2012, the US FDA approved Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis C (CHC), so that hepatitis C patients with poor prognosis due to low platelet count can start and maintain interferon based standard therapy for liver diseases. On february3,2014, GlaxoSmithKline announced that the FDA granted the breakthrough treatment drug qualification of Eltrombopag for the treatment of hemopenia in patients with severe chemicalbook aplastic anemia (SAA) who did not fully respond to immunotherapy. On August 24, 2015, the US FDA approved Eltrombopag for the treatment of thrombocytopenia in adults and children aged 1 year and over with chronic immune thrombocytopenia (ITP) who have insufficient response to corticosteroids, immunoglobulins or splenectomy. On january4,2018, Eltrombopag was approved to be listed in China for the treatment of primary immune thrombocytopenia (ITP).

We constantly believe that one’s character decides products’ high quality, the details decides products’ high-quality ,together with the REALISTIC,EFFICIENT AND INNOVATIVE crew spirit for Hot-selling High Quality CAS 78-96-6 99% Amino-2-Propanol / Isopropanolamine/ Monoisopropanolamine (MIPA), We are going to make increased attempts to aid domestic and international buyers, and generate the mutual benefit and win-win partnership between us. we are eagerly waiting for your sincerely cooperation.
Hot-selling China Mipa and Monoisopropanolamine, We integrate design, manufacture and export together with more than 100 skillful workers, strict quality controlling system and experienced technology.We keep long term business relationships with wholesaler and distributors form more than 50 countries, such as USA, UK, Canada, Europe and Africa etc.